This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lidon, R. M. Articles by Levesque, J. Search for Related Content PubMed PubMed Citation Articles by Lidon, R. M. Articles by Levesque, J.

Circulation, Vol 89, 1567-1572, Copyright © 1994 by American Heart Association

ARTICLES

A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction

RM Lidon, P Theroux, J Lesperance, B Adelman, R Bonan, D Duval and J Levesque
Department of Medicine, Montreal Heart Institute, Quebec, Canada.

BACKGROUND: The success of streptokinase in acute myocardial infarction is hampered by the high failure rate to achieve early reperfusion. This study evaluates the possible benefit of Hirulog (Biogen, Cambridge, Mass), a direct thrombin inhibitor, as adjunct therapy to streptokinase to enhance early patency and prevent rethrombosis. Heparin has been shown to be of very limited benefits in this setting. METHODS AND RESULTS: Forty-five patients were randomized to Hirulog or heparin (2:1 ratio). Coronary angiography documented a TIMI 2 or 3 flow after 90 minutes in 77% of the patients treated with Hirulog and streptokinase and in 47% of patients treated with heparin and streptokinase (P < .05) and after 120 minutes in 87% and 47% of patients, respectively (P < .01). TIMI 3 flow was established in 77% of patients with Hirulog compared with 40% with heparin (P < .02). The clinical outcome and the bleeding rate was also favorable to Hirulog; no reocclusion was observed at late angiography performed 4.7 days later. CONCLUSIONS: Hirulog in this pilot study significantly improved the early patency rate of the infarct-related artery with a favorable clinical profile. This new direct thrombin inhibitor exhibits promise as adjunctive therapy to thrombolysis.

This article has been cited by other articles:

				P. Eichler, N. Lubenow, U. Strobel, and A. Greinacher Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin Blood, January 15, 2004; 103(2): 613 - 616. [Abstract] [Full Text] [PDF]

				G. N. Levine, M. N. Ali, and A. I. Schafer Antithrombotic Therapy in Patients With Acute Coronary Syndromes Arch Intern Med, April 9, 2001; 161(7): 937 - 948. [Abstract] [Full Text] [PDF]

				S. M. Bates and J. I. Weitz Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin Cardiovasc Res, February 1, 1999; 41(2): 418 - 432. [Abstract] [Full Text] [PDF]

				J. I. Weitz, B. Leslie, and M. Hudoba Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors Circulation, February 17, 1998; 97(6): 544 - 552. [Abstract] [Full Text] [PDF]

				D. Cummins and E. Hill Heparin-Induced Thrombocytopenia Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 349 - 365. [Abstract] [PDF]

				H. D. White, P. E. Aylward, M. J. Frey, A. A. J. Adgey, R. Nair, W. S. Hillis, Y. Shalev, M. A. Brown, J. K. French, R. Collins, et al. Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) Circulation, October 7, 1997; 96(7): 2155 - 2161. [Abstract] [Full Text]

				D. R. Abendschein, Y. Y. Meng, S. Torr-Brown, and B. E. Sobel Maintenance of Coronary Patency After Fibrinolysis With Tissue Factor Pathway Inhibitor Circulation, August 15, 1995; 92(4): 944 - 949. [Abstract] [Full Text]

				J. J. Cook, G. R. Sitko, B. Bednar, C. Condra, M. J. Mellott, D.-M. Feng, R. F. Nutt, J. A. Shafer, R. J. Gould, and T. M. Connolly An Antibody Against the Exosite of the Cloned Thrombin Receptor Inhibits Experimental Arterial Thrombosis in the African Green Monkey Circulation, June 15, 1995; 91(12): 2961 - 2971. [Abstract] [Full Text]

				P. Theroux, F. Perez-Villa, D. Waters, J. Lesperance, F. Shabani, and R. Bonan Randomized Double-Blind Comparison of Two Doses of Hirulog With Heparin as Adjunctive Therapy to Streptokinase to Promote Early Patency of the Infarct-Related Artery in Acute Myocardial Infarction Circulation, April 15, 1995; 91(8): 2132 - 2139. [Abstract] [Full Text]